congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Edoxaban
EuroPCR 2024 | May 14-17, 2024
Major bleeding after TAVI in the ENVISAGE-TAVI AF trial: A risk-assessment score
Oral
Edoxaban
EuroPCR 2024 | May 14-17, 2024
Outcomes in patients with atrial fibrillation after TAVI analysed by age: ENVISAGE-TAVI AF results
Oral
Edoxaban
EuroPCR 2024 | May 14-17, 2024
Patient-reported outcomes from the ENVISAGE-TAVI AF trial using the win ratio analysis